A study testing whether a GLP-1 medicine, semaglutide, can help people with narcotic-related disorders use less opioids.
Recruiting now. Registry record last updated July 28, 2026.
- Who can join
- Adults 18 to 75, have opioid use disorder, BMI 18+.
- What you take
- semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 2.3 years; your own time in it is usually shorter.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: Opioid Use Disorder. Also studied in: Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid.
Full scientific study title: GLP-1R Agonist Treatment for Opioid Use Disorder.
Who can join
Adults 18 to 75, have opioid use disorder, BMI 18+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Age 18 to 75 years.
- Body mass index (BMI) \> 18.
- Able and willing to provide informed consent prior to any study-related activities.
- Current diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 Opioid Use Disorder (OUD) as per the Mini International Neuropsychiatric Interview (MINI) or per the site clinic diagnosis. Patients are eligible if they have a MINI \> 3 ("moderate" or "severe" in the "Specify If" box in the Substance Use Disorder (Non-Alcohol) module for the category of opiates).
- Currently receiving outpatient treatment for OUD and at least 2 weeks on buprenorphine (BUP) or 4 weeks on methadone at the study site and/or at an associated clinic at the time of enrollment.
Key exclusion criteria
- Age \< 18 or \> 75 years.
- BMI \<18.
- Individuals who are pregnant, planning pregnancy, breastfeeding, or unwilling to use adequate contraceptive measures.
- Current use of glucagon-like peptide 1 receptor (GLP-1R) agonist.
- History of angioedema, serious hypersensitivity reaction, or anaphylactic reaction to semaglutide or another GLP-1R agonist.
Where this trial is enrolling
This trial has 4 sites across 4 states. Contact a site coordinator directly to start screening.
Maryland1 site
- University of Maryland BaltimoreBaltimore, Maryland
Massachusetts1 site
- Stanley Street Treatment and ResourcesFall River, Massachusetts
New York1 site
- NYU Langone HealthNew York, New York
Pennsylvania1 site
- Pennsylvania Psychiatric InstituteHarrisburg, Pennsylvania
Timeline
Started enrolling: January 13, 2025. Expected completion: April 2027. Last updated on ClinicalTrials.gov: July 28, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
